{
  "docId": "019de075-2fc9-715d-b6e1-faa3fd3ed1eb",
  "docSlug": "be407bbae8f9e005c3f7268aea2b4f13",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 34 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 34,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "comparison_table",
  "function": "cite_precedent",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a case study to validate the business/clinical model of combination therapies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-2fc9-715d-b6e1-faa3fd3ed1eb/7",
  "deckHref": "/decks/019de075-2fc9-715d-b6e1-faa3fd3ed1eb",
  "deckJsonHref": "/decks/019de075-2fc9-715d-b6e1-faa3fd3ed1eb.json",
  "deckAnchorHref": "/decks/019de075-2fc9-715d-b6e1-faa3fd3ed1eb#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.65,
        "y": 0.28
      },
      "kind": "list",
      "text": "Successful combination strategies in neurology: Alzheimer's (Donepezil + Memantine), Parkinson's (Entacapone + levodopa/carbidopa), ALS (Sodium Phenybuterate + Taurursodiol), SMA (Onasemnogene + Nusinersen), Epilepsy (Lamotrigine + Valproate/Carbamazepine)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c618869f-58ac-4499-8755-6f4f4fba13ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.09,
        "y": 0.3
      },
      "kind": "paragraph",
      "text": "Case Study: Amylyx (NASDAQ: AMLX)\nMarket Cap: $1.75 B (June 2023)\nDrug: ALS Combination Therapy of generic + supplement\nPrice: $158,000/ year\nEstimated 2026 Sales: $1.1B/ year*",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07a711b7-f911-48fd-9e67-8a8e8a89f383",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.09,
        "y": 0.73
      },
      "kind": "paragraph",
      "text": "The FDA approved Amylyx's drug, AMX0035 (Relyvrio), in September 2022 after Phase 2 clinical trial attenuated diseases progression (ALSFRSr) by 25% when compared to placebo",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df9cce3e-0400-4b5f-8c6d-4ffdb86ae172",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "Current Strategies: Synergistic MOAs OR Improved PK",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b64f8609-6d2f-448a-9b7d-a511a3dd3d35",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "Potential of Combined Therapy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "448bea71-9a5f-4be3-85e6-37c18f470d09",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "argument-from-analogy",
      "slug": null,
      "matchId": "969a2b92-316a-48ad-8b87-8955fb12a311",
      "evidence": "Uses Amylyx case study and existing neurology combinations to justify the company's own strategy.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 34,
      "from": 5,
      "beatId": "e49a51a7-5d8f-48c6-bbde-aebd1ab25027",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents PrimeC as a potential solution to the problem of limited ALS treatment options.",
      "position": 2,
      "confidence": 0.9,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 34,
      "from": 5,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "c317ff20-e462-4b87-8745-365a96908ee6",
      "evidence": "The document outlines the development process and clinical trials for PrimeC.",
      "position": 1,
      "objective": "What are the key tasks that need to be done to develop PrimeC as a treatment for ALS?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.8,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}